Search results for: Innovation Policy Prize
Filter search results
Industrial Policy and the Pharmaceutical Industry
1 January 1995
…and of the pharmaceutical industry, drawing lessons for Europe. Grabowski examines the potential impact of price control on innovation, drawing on a study of innovation in the USA. Finally Holmes…
Innovation in Oncology: Real Option Value and Path Dependence
29 April 2014
Real Option Value and Path Dependence in Oncology Innovation. Based on an OHE Lunchtime Seminar, this Seminar Briefing addresses a persistent issue: how to adequately reward innovation through the pricing…
Innovation in Medicines: Can We Value Progress?
1 August 2010
…of any problems arising from innovation path dependency in health technologies. Elements of the policy and research agendas that affect the amount and type of innovation were debated. The group…
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
To what extent can R&D incentives, competition and other factors facilitate access to highly valuable and costly pharmaceutical innovations? In the pharmaceutical industry, intellectual property (IP) rights protection, including patents,…
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
1 June 2022
…new drugs coming to market, but the value, not the volume of innovation, matters most for patients. For these reasons and others which we expand upon in this report, policymakers…
H.R. 3 is the Wrong Policy for the Wrong Problem
10 September 2021
US policy makers are discussing an attempt to lower prescription drug spending in the US. US policy makers are currently discussing the Elijah E. Cummings Lower Drug Costs Now Act…
The Lower Drug Costs Now Act and Pharmaceutical Innovation
1 September 2021
The US spends significantly more on healthcare per person than other wealthy countries. H.R. 3 is a recent policy proposal aimed at reducing national spending on prescription drugs, one component…
New: Antimicrobial Drug Incentives
6 April 2011
…hybrid push-pull approach to encouraging innovation. OHE has just made available Research Paper 11/02, Incentives for New Antimicrobial Drugs. Antimicrobial resistance (AMR) is becoming a major global public health threat…
Antibacterials: Roundtable Addresses the Critical Issues
10 November 2011
…challenge and thinking through possible responses. Earlier this year, OHE launched its publication, New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options and also hosted a roundtable with…